ArticleNature communications2017
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 1 pooled it
14.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 1 synthesis or guideline pooled it, 343 citations in OpenAlex.
- Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Stemness in Colon Cancer.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids.Oncoimmunology · 2026Article
- Patient-derived organoids for personalized drug response profiling and multi-omics integration in oral squamous cell carcinoma.iScience · 2026Article
- Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity.Cell reports. Medicine · 2026Article
- Deconstructing cancer in 3D: models, mechanisms, and personalized solutions.Molecular cancer · 2026Review
- Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS/BRAF Wild-type Metastatic Colorectal Cancer.Journal of gastrointestinal cancer · 2026Review
- Establishment and genomic characterization of patient-derived organoids from gastric-type cervical adenocarcinoma.Journal of gynecologic oncology · 2026Article
- BRAFJournal of experimental & clinical cancer research : CR · 2026Article
- RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research.Scientific reports · 2026Article
- The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.Cancer discovery · 2026Article
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Nidogen 1-enriched extracellular vesicles promote liver metastasis by inducing EMT and activating stellate cells.iScience · 2025Article
- Tumor organoids in cancer medicine: from model systems to natural compound screening.Pharmaceutical biology · 2025Review
- Single-cell multiomic modelling of early metastatic events promoted by the extracellular matrix.British journal of cancer · 2025Article
- Comprehensive dissection of rectal cancer organoids in responses to chemoradiation.Cell reports. Medicine · 2025Article
- Aurora kinase A drives non-canonical YAP1/TAZ crosstalk to sustain primary resistance to anti-EGFR therapies in colorectal cancer.Molecular therapy. Oncology · 2025Article
- Patient-Derived Organoid Biobanks for Translational Research and Precision Medicine: Challenges and Future Perspectives.Journal of personalized medicine · 2025Review
- SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Impact of enzymatic isolation on the propagation efficiency of patient-derived colorectal cancer organoids.Scientific reports · 2025Article
135 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
46 authors at 14 institutions in 7 countries.
Moritz SchütteAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Thomas RischMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.
Nilofar Abdavi-AzarMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.
Karsten BoehnkeEli Lilly and Company, Lilly Research Laboratories, Quantitative Biology, Avda. de la Industria 30, Alcobendas, 28108 Madrid, Spain.
Dirk SchumacherCharité-Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology, Charitéplatz 1, 10117 Berlin, Germany.
Marlen KeilExperimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Reha YildirimanAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Christine JandrasitsMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.ORCID 0000-0003-1357-4401
Tatiana BorodinaAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Vyacheslav AmstislavskiyMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.ORCID 0000-0002-1384-7599
Catherine L WorthMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.
Caroline SchweigerInstitute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria.
Sandra LiebsCharité-Universitätsmedizin, Charitéplatz 1, 10117 Berlin, Germany.
Martin LangeBayer Pharma AG, Müllerstraße 178, 13353 Berlin, Germany.ORCID 0000-0002-4045-3915
Hans-Jörg WarnatzMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.
Lee M ButcherUCL Cancer Institute, University College London, London WC1E 6BT, UK.
James E BarrettUCL Cancer Institute, University College London, London WC1E 6BT, UK.
Marc SultanMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.
Christoph WierlingAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Nicole Golob-SchwarzlInstitute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria.
Sigurd LaxDepartment of Pathology, Hospital Graz Süd-West, Göstinger Straße 22, 8020 Graz, Austria.
Stefan UranitschDepartment of Surgery, Hospital Brothers of Charity Graz, Marschallgasse 12, 8020 Graz, Austria.
Michael BeckerExperimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Yvonne WelteCharité-Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology, Charitéplatz 1, 10117 Berlin, Germany.
Joseph Lewis ReganBayer Pharma AG, Müllerstraße 178, 13353 Berlin, Germany.
Maxine SilvestrovCharité-Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology, Charitéplatz 1, 10117 Berlin, Germany.
Inge KehlerCharité-Universitätsmedizin, Charitéplatz 1, 10117 Berlin, Germany.
Alberto FusiCharité-Universitätsmedizin, Charitéplatz 1, 10117 Berlin, Germany.
Thomas KesslerAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Ralf HerwigMax Planck Institute for Molecular Genetics, Department of Computational Molecular Biology, Ihnestrasse 73, D-14195 Berlin, Germany.ORCID 0000-0002-9335-1760
Ulf LandegrenDepartment of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Box 815, SE-751 08 Uppsala, Sweden.ORCID 0000-0002-7820-1000
Dirk WienkeMerck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.
Mats NilssonDepartment of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Box 815, SE-751 08 Uppsala, Sweden.
Juan A VelascoEli Lilly and Company, Lilly Research Laboratories, Quantitative Biology, Avda. de la Industria 30, Alcobendas, 28108 Madrid, Spain.
Pilar Garin-ChesaBoehringer Ingelheim RCV GmbH &Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Wien, Austria.
Christoph ReinhardEli Lilly and Company, Lilly Research Laboratories, Oncology Translational Research, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Stephan BeckUCL Cancer Institute, University College London, London WC1E 6BT, UK.ORCID 0000-0001-5290-2151
Reinhold SchäferCharité-Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology, Charitéplatz 1, 10117 Berlin, Germany.
Christian R A RegenbrechtCharité-Universitätsmedizin Berlin, Institute of Pathology, Laboratory for Molecular Tumour Pathology, Charitéplatz 1, 10117 Berlin, Germany.
David HendersonBayer Pharma AG, Global External Innovation &Alliances, Müllerstraße 178, 13353 Berlin, Germany.
Bodo LangeAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Johannes HaybaeckInstitute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria.ORCID 0000-0001-5518-3359
Ulrich KeilholzCharité-Universitätsmedizin, Charitéplatz 1, 10117 Berlin, Germany.
Jens HoffmannExperimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Hans LehrachAlacris Theranostics GmbH, Fabeckstr. 60-62, D-14195 Berlin, Germany.
Marie-Laure YaspoMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics/Otto Warburg Laboratory Gene Regulation and Systems Biology of cancer, Ihnestrasse 73, D-14195 Berlin, Germany.ORCID 0000-0002-9555-9979
Max Planck Institute for Molecular Genetics · DEAlacris (Germany) · DEHelios Hospital Berlin-Buch · DECharité - Universitätsmedizin Berlin · DEBayer (Germany) · DEMedical University of Graz · ATUniversity College London · GBEli Lilly (Spain) · ESGerman Cancer Research Center · DEGraz University Hospital · ATUppsala University · SEBoehringer Ingelheim (Austria) · ATEli Lilly (United States) · USMerck (Germany) · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular sub-groups because of the loss of human stroma. Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.
Indexed as
Xenograft Model Antitumor AssaysAdolescentAdultAgedAged, 80 and overAnimalsAntineoplastic Agents, ImmunologicalBiomarkers, TumorCetuximabColorectal NeoplasmsErbB ReceptorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMiddle AgedAntineoplastic Agents, ImmunologicalBiomarkers, TumorCetuximabErbB Receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.